Search Results

Effectiveness of lumacaftor/ivacaftor initiation in children with cystic fibrosis aged 2 through 5 years on disease progression: Interim results from an ongoing registry-based study.

• Authors : Kim, Claire¹ (AUTHOR) ; Higgins, Mark¹ (AUTHOR); Liu, Lingyun¹ (AUTHOR)

Subjects: *CYSTIC fibrosis; *DISEASE progression; *MEDICAL registries

• Source: Journal of Cystic Fibrosis. May2024, Vol. 23 Issue 3, p436-442. 7p.

Record details

WS12.1 An exploratory study to determine the impact of lumacaftor/ivacaftor (LUM/IVA) on disease progression in children 2 through 5 years of age with cystic fibrosis homozygous for F508del-CFTR (F/F).

• Authors : Stahl, M. (AUTHOR); Roehmel, J. (AUTHOR); Eichinger, M. (AUTHOR)

Subjects: *CYSTIC fibrosis; *DISEASE progression; *AGE

• Source: Journal of Cystic Fibrosis. 2021 Supplement, Vol. 20, pS22-S23. 2p.

Record details

P066 Disease progression and burden in patients with cystic fibrosis homozygous for F508del across Europe in an observational registry (VOICE Study).

• Authors : Mckone, E. (AUTHOR); Castellani, C. (AUTHOR); Heijerman, H. (AUTHOR)

Subjects: *CYSTIC fibrosis; *DISEASE progression; *CHILD patientsEUROPE

• Source: Journal of Cystic Fibrosis. 2019 Supplement 1, Vol. 18, pS75-S76. 2p.

Record details

121 Evaluation of lung disease progression after introduction of lumacaftor/ivacaftor in young children.

• Authors : Slimmen, L. (AUTHOR); Horati, H. (AUTHOR); Mager, D. (AUTHOR)

Subjects: *LUNG diseases; *DISEASE progression

• Source: Journal of Cystic Fibrosis. 2022 Supplement 2, Vol. 21, pS72-S72. 1p.

Record details

567: Optimization of methods of interrogating large proteomic data sets for disease progression prediction in CF.

• Authors : Gecili, E. (AUTHOR); Cheng, Y. (AUTHOR); Siefert, M. (AUTHOR)

Subjects: *DISEASE progression; *FORECASTING

• Source: Journal of Cystic Fibrosis. 2021 Supplement 2, Vol. 20, pS268-S268. 1p.

Record details

Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study.

• Authors : Carr, Siobhán B^1,2 (AUTHOR) ; McClenaghan, Elliot^1,3,4 (AUTHOR); Elbert, Alexander^1,5 (AUTHOR)

Subjects: *CYSTIC fibrosis; *DISEASE progression; *COVID-19

• Source: Journal of Cystic Fibrosis. Jul2022, Vol. 21 Issue 4, pe221-e231. 11p.

Record details

News.

Subjects: *CYSTIC fibrosis; *DISEASE progression; *COMORBIDITY

• Source: Journal of Cystic Fibrosis. Mar2015, Vol. 14 Issue 2, p167-168. 2p.

Record details

228 Low-density neutrophils in adults with cystic fibrosis are associated with lung disease progression and display distinct antimicrobial capacity.

• Authors : Murru, A. (AUTHOR); Vadeboncoeur, N. (AUTHOR); Therrien, A. (AUTHOR)

Subjects: *CYSTIC fibrosis; *LUNG diseases; *DISEASE progression

• Source: Journal of Cystic Fibrosis. 2023 Supplement 3, Vol. 22, pS116-S117. 2p.

Record details

Modeling cystic fibrosis disease progression in patients with the rare CFTR mutation P67L.

• Authors : MacKenzie, Isobel E.R.¹; Paquette, Valerie¹; Gosse, Frances²

Subjects: *CYSTIC fibrosis; *DISEASE progression; *CYSTIC fibrosis transmembrane conductance regulator

• Source: Journal of Cystic Fibrosis. May2017, Vol. 16 Issue 3, p335-341. 7p.

Record details

411 Disease progression in patients (pts) with cystic fibrosis (CF) treated with ivacaftor (IVA): analysis of real-world data from the UK CF Registry.

• Authors : Bessonova, L.; Volkova, N.; Higgins, M.

Subjects: *CYSTIC fibrosis treatment; *DISEASE progression; *CYSTIC fibrosis

• Source: Journal of Cystic Fibrosis. Jun2017 Supplement 1, Vol. 16, pS167-S167. 1p.

Record details